Del 1153
Del 1153 i serien Advances in Experimental Medicine and Biology
1 094 kr
Beställningsvara. Skickas inom 10-15 vardagar. Fri frakt över 249 kr.
Beskrivning
It also discusses metastatic renal cell carcinoma – a global scourge with an extremely poor long-term survival prognosis, the course and sequelae of renal cell carcinoma, as well as advances in targeted molecular therapy with sunitinib, a receptor tyrosine kinase inhibitor.